Royalty Pharma (NASDAQ:RPRX) Downgraded to Hold Rating by Wall Street Zen

Key Points

• Royalty Pharma has been downgraded by Wall Street Zen from a "buy" rating to a "hold" rating.
• Analysts have varying ratings for Royalty Pharma, with a consensus rating of "Buy" and a price target of $48.00.
• The company's recent earnings report showed an EPS of $1.14, exceeding analysts' expectations, despite revenues falling short of estimates.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday.

Other equities research analysts also recently issued research reports about the stock. Citigroup lifted their price target on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a "buy" rating in a research note on Tuesday, July 22nd. Morgan Stanley boosted their target price on shares of Royalty Pharma from $51.00 to $54.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. According to data from MarketBeat, Royalty Pharma has a consensus rating of "Buy" and a consensus price target of $48.00.

Royalty Pharma Stock Down 0.9%

RPRX opened at $36.36 on Friday. Royalty Pharma has a fifty-two week low of $24.05 and a fifty-two week high of $38.00. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.26 and a quick ratio of 1.26. The firm's fifty day moving average price is $36.36 and its two-hundred day moving average price is $34.28. The company has a market capitalization of $21.20 billion, a P/E ratio of 21.02, a P/E/G ratio of 2.29 and a beta of 0.58.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.04. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. The firm had revenue of $578.67 million for the quarter, compared to the consensus estimate of $750.06 million. On average, analysts anticipate that Royalty Pharma will post 4.49 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Merit Financial Group LLC bought a new position in shares of Royalty Pharma in the first quarter valued at about $252,000. M&T Bank Corp raised its holdings in shares of Royalty Pharma by 23.4% in the first quarter. M&T Bank Corp now owns 28,967 shares of the biopharmaceutical company's stock valued at $902,000 after buying an additional 5,500 shares during the last quarter. Yousif Capital Management LLC bought a new position in shares of Royalty Pharma in the first quarter valued at about $275,000. Asset Management One Co. Ltd. raised its holdings in shares of Royalty Pharma by 8.0% in the first quarter. Asset Management One Co. Ltd. now owns 164,931 shares of the biopharmaceutical company's stock valued at $5,134,000 after buying an additional 12,148 shares during the last quarter. Finally, Amalgamated Bank raised its holdings in shares of Royalty Pharma by 4.4% in the first quarter. Amalgamated Bank now owns 20,423 shares of the biopharmaceutical company's stock valued at $636,000 after buying an additional 866 shares during the last quarter. 54.35% of the stock is owned by institutional investors.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.